NEVVI Medicare utilization intelligence

← back

NUMAN, YAZANMD NPI 1801243738 Clinician

Hematology-Oncology · ORLAND PARK, IL

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 11 years since medical school (class of 2015, self-reported to CMS)
Location ORLAND PARK, IL · NPPES registered location
Active in data Billed Medicare 2022–2024 (3 consecutive years)
Scale 60 codes billed · 97,090 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20232026
NORTHWESTERN MEDICAL FACULTY FOUNDATION
2023–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-09

Year: 2024 · 2023 · 2022 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9075 Injection, cyclophosphamide, not otherwise specified, 5 mg
J0897 Injection, denosumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J9305 Injection, pemetrexed, not otherwise specified, 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
J0461 Injection, atropine sulfate, 0.01 mg
J2469 Injection, palonosetron hcl, 25 mcg
36415 Insertion of needle into vein for collection of blood sample
J0640 Injection, leucovorin calcium, per 50 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J9190 Injection, fluorouracil, 500 mg
J9206 Injection, irinotecan, 20 mg
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96375 Injection of additional new drug or substance into vein
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
J2506 Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
96415 Administration of chemotherapy into vein, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
J9000 Injection, doxorubicin hydrochloride, 10 mg
96372 Injection of drug or substance under skin or into muscle
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96411 Administration of additional new drug or substance into vein using push technique
J3475 Injection, magnesium sulfate, per 500 mg
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
J1200 Injection, diphenhydramine hcl, up to 50 mg
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99496 Transitional care management services for problem of high complexity
J7030 Infusion, normal saline solution , 1000 cc
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
96360 Infusion into a vein for hydration, 31-60 minutes
99443 Telephone medical discussion with physician, 21-30 minutes
J3490 Unclassified drugs
96377 Application of on-body injector for under skin injection
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96523 Irrigation of implanted venous access drug delivery device
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99442 Telephone medical discussion with physician, 11-20 minutes
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
96374 Injection of drug or substance into vein
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
36593 Declotting of central venous tube

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.